Background: Synovial sarcoma is a soft tissue malignancy with a predilection for adolescents and young adults. Despite recent improvements in the understanding
Introduction
Synovial sarcoma remains a deadly soft tissue mesenchymal malignancy that primarily affl icts adolescents and young adults. Although it is a rare tumor in terms of numbers of patients diagnosed with synovial sarcoma, its societal impact is magnifi ed by the young age group affected and the high mortality associated with synovial sarcoma. Much has been learned in recent years about its biology, but as with most soft tissue sarcomas, therapeutic advances have been limited. 1 Metastatic disease still portends a poor prognosis. 2 Long-term follow-up of patients with initial localized disease reveals an increasing proportion with systemic relapse. 3 Recurrent balanced translocations between the X and 18 chromosomes were identifi ed in synovial sarcoma cells in the 1980s. 4 It was later noted that these translocations generated fusion oncoproteins composed of the amino-terminus of the SYT gene and the carboxy-terminus of one of the SSX genes, most commonly SSX1 or SSX2. 5, 6 The discovery of this, and many other balanced translocation fusion oncogenes in sarcomas, began as associations but quickly came to defi ne each tumor type, even at times trumping histologic diagnosis. 7 Modeling attempts have even proven the suffi ciency of some of these fusion oncoproteins to drive subtype-specifi c sarcomagenesis, arguing for an initiatory biological role of these translocations. [8] [9] [10] Nonetheless, molecular diagnostic advances and improved understanding of transformative synovial sarcomagenesis itself have not yet materially changed therapeutic strategies or success rates.
Identifying the Problem
Sarcoma, which is Greek for "fl eshy tumor," includes a group of malignancies with a broad variety of biological behaviors. As in any area of therapeutic knowledge, the defi nition of a treatable diagnostic entity requires a combination of "lumping and splitting" to defi ne distinct, smaller groups with more consistent biology on which to focus treatment. Sarcoma presents major challenges to "lumping and splitting" by virtue of the many different characteristics by which subgroups may be divided, few of which create corroborative or overlapping subgroup distinctions. About one-third of sarcomas have subtypespecifi c balanced translocations, while the remaining two-thirds have more complex karyotypes. Sarcomas have a bimodal age distribution, most frequently arising in adolescents and young adults and the others occurring in the middle-aged and elderly. While any mesenchymal tissue can be involved by sarcomas, about one-third oc- -Schematic representing IGF1R/HER2 intersecting pathways. Either IGF signaling or HER2 dimerizing with HER3 on ligand (lig) binding will lead to activation of phosphoinositol 3 kinase (PI3K), which then activates Akt and its downstream effectors. Either IGF signaling or HER2 dimerizing with HER1 (also EGFR) on ligand binding will activate GRB2 and SOS, which then activate RAS/RAF signaling.
curs in the skeleton and two-thirds in the soft tissues. Dividing sarcomas generally into two groups by any of these methods still renders heterogeneous groups, with wide biological variation within each group. Histologic subtyping provides another method of defi ning sarcomas, by which approximately 100 different groups can be identifi ed. Molecular subtyping can now divide each histologic group even further. The greatest challenge to these more biologically specifi c divisions is the small numbers in any group created. 11 Just over 10,000 sarcomas of any type occur in the United States each year. 12 The incidence of any specifi c subtype is far smaller.
The Children's Oncology Group (COG), the largest sarcoma trial-organizing entity in North America, divides sarcomas into Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and nonrhabdomyosarcoma soft tissue sarcoma (which includes synovial sarcoma). COG trials accrue approximately 100 patients per year to this last group. Sarcoma Alliance for Research through Collaboration (SARC), the largest group focused on trials for sarcomas in adults, has trials specifi c for bone sarcomas, soft tissue sarcomas, uterine leiomyosarcoma, dermatofi brosarcoma protuberans, gastrointestinal stromal tumor, malignant peripheral nerve sheath tumor, and osteosarcoma. The SARC, which includes 36 cancer centers, recruits approximately 300 patients each year to their varied protocols.
While the small numbers of new diagnoses per year make lumping into groups by type an attractive practice for these trials, lumping sarcoma types together compromises the validity of the outcomes in important ways. First, each sarcoma subtype has unique prognostic implications with regard to the expected natural history. The common algorithms and nomograms used to prognosticate sarcoma relapse or disease-specifi c death include subtype as a major factor. [13] [14] [15] Second, trials have already shown some clear disparities between subtypes in terms of responses to given chemotherapeutic regimens. For example, randomized trials testing the addition of ifosfamide to the standard treatment regimens for osteosarcoma and Ewing sarcoma generated opposite results for each subtype, improving survival for Ewing sarcoma patients and worsening it for osteosarcoma patients. 16, 17 These predictive implications of subtype might mask a signifi cant benefi t from a specifi c regimen for a specifi c sarcoma subtype, especially if tested within a single group of combined diagnoses. Such a masking of therapeutic benefi t already has been proposed for synovial sarcoma. Although trials of regimens including doxorubicin and/or ifosfamide demonstrated no survival benefi t for large, deep-location, high-grade soft tissue sarcomas as a whole, retrospective reviews of the synovial sarcoma patients treated in those trials have shown variable survival benefi t. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Partly through strong, vocal opinions and partly through a desire to conquer such a deadly cancer, the standard of care adopted throughout most of the United States and Canada is to offer combination doxorubicin/ifosfamide chemotherapy for patients with synovial sarcoma despite the absence of any controlled, prospective evidence of benefi t. Practitioners trust that the randomized controlled trials' negative results cannot be applied to the subgroup of synovial sarcomas. 28 The collection of the ideal randomized controlled evidence is challenging. Approximately 300 patients in the United States are diagnosed with synovial sarcoma each year. Unlike patients with Ewing sarcoma or osteosarcoma, whose natural histories yield 80% to 95% death by disease in the absence of systemic treatments, those with synovial sarcoma have 40% to 60% survival following effective local control without systemic therapies. That somewhat more favorable (although hardly favorable in any absolute sense) natural history demands higher numbers for statistical detection of benefi t. To have suffi cient power to rule out a difference of at least 20% (eg, an increase from 50% survival to 60% survival) between two treatment arms, every synovial sarcoma patient in North America would have to be recruited to a single two-arm trial for an entire year. Such recruitment success is clearly not possible. More realistic recruitment might require 5 years for each trial as well as cross-continental recruitment support. Obtaining a real answer in 7 years (5 years of recruitment and 2 years of follow-up) is not unreasonable, but such a protocol can answer only a single question at a time, necessitating the prioritization of the most clinically critical questions. In addition to the time and expense of organizing such trials, the patients available for recruitment are a scarce resource, which becomes the rate-limiting step in advancing treatment for synovial sarcoma.
Multiplicity of Potential Agents
As mentioned above, the utility of standard cytotoxic chemotherapy is not well established for synovial sarcoma, and the particular cytotoxic regimens that might provide the most benefi t have not yet been established. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Anthracycline antibiotics and alkylating agents are most commonly used today to treat synovial sarcoma. Retrospective data are confl icting about the utility of either class in general for synovial sarcoma, [29] [30] [31] [32] but there are more favorable reports of ifosfamide with or without doxorubicin. 18, 20, 22, 24, 26, 33, 34 Tumor response rates are typically reported to be around 50%. Other cytotoxic agents, including trabectedin and tasidotin (used only in xenografts so far), have been studied, most with mixed results. [35] [36] [37] Another class of chemotherapeutic agents suspected to have some activity against synovial sarcomas is the newer group of antiangiogenesis agents. [38] [39] [40] Synovial sarcoma displays a characteristic hemangiopericytomatous vascular pattern under the microscope, suggestive that angiogenesis is critical to its establishment and growth. 41 A few synovial sarcoma patients have been included in general trials of antiangiogenesis agents for solid tumors. Some responses have been reported from these patients. Among 37 patients with synovial sarcoma who were treated with pazopanib, 18 experienced progressionfree survival at 12 weeks. 38 One of 2 patients noted to respond to a phase I trial of squalamine was a synovial sarcoma patient. 40 These case reports are suffi cient to suggest that this class of antiangiogenic agents merits further investigation, but no follow-up studies have yet been reported. As with other sarcoma subtypes, there has been recent interest in druggable targets in the IGF1R/mTOR/ Akt pathway (Fig 1) . 42 Akt and mTOR have been noted to be constitutively active in some synovial sarcomas, and their activation correlates with metastasis. 43 Synovial sarcomas positive for HER1 did not respond to gefi tinib, 44 but HER2 activation has been noted in head and neck cases of synovial sarcoma. 45 One patient with advanced synovial sarcoma treated with fi gitumumab demonstrated stable disease for 4 months. 46 Sorafenib has been effective on synovial sarcoma cell lines in culture and has been tried in patients with metastatic disease. 47, 48 While preliminary clinical data are scant, IGF1R/mTOR/Akt is an active pathway in synovial sarcoma for which many new agents are becoming available.
Inhibitors of antiapoptotic pathways (Fig 2) such as Bcl-2 inhibitors also show theoretical promise for synovial sarcoma. 49 Although no pertinent trials have been reported to include synovial sarcoma patients, Bcl-2 is upregulated in the common expression profi le of synovial sarcoma. 50 High levels of Bcl-2 in synovial sarcoma are thought to be a major mechanism of chemoresistance by allowing the tumor to escape the apoptotic drive from usual cytotoxic agents. Specifi c in vitro experiments to inhibit Bcl-2 have proven successful at slowing the growth of synovial sarcoma and inducing apoptosis in its cell lines in conjunction with cytotoxic agents. 51 Other apoptotic pathways remain intact in synovial sarcoma cells, including tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), 52 and may provide other candidate loci that can be targeted.
Finally, inhibitors of the histone deacetylase complex (HDACi) are of interest to the management of synovial sarcoma. SYT-SSX proteins have been shown to associate with polycomb group proteins, regulating expression of certain targets by epigenetic modifi cations of histones. One of the highlighted targets of these epigenetic silencing effects of SYT-SSX is the tumor suppressor early growth response 1 (EGR1). 53 Increased expression of EGR1 and subsequent phosphatase and tensin homolog (PTEN)-mediated apoptosis can be achieved in synovial sarcoma cell lines by the administration of FK228, an HDACi. 54, 55 Additionally, synergism has been noted between an HDACi and the proapoptotic 17-AAG compound, which downregulates heat shock protein 90. 56 This area of histone deactylation is enhanced by recent basic research fi ndings and holds promise for therapeutic benefi ts yet to materialize.
Prioritizing Agents
One common method of prioritizing agents for a given disease is to pilot them in small numbers in patients who already have failed standard treatment regimens and are moribund with progressively advancing disease. The search for a response to any agent can be desperate in this setting for both the patient and the practitioner. Knowledge gained from the slowing of progression -or lack thereof -of widely metastatic, multiple, chemoexposed and resistant aggressive tumors in patients with often poor functional status may be diffi cult to apply to the management of otherwise healthy patients with treatment-naive, microscopic, systemic disease that is hoped to be eradicated in the primary tumor setting. Nonetheless, this remains one utilized method for identifying effective agents.
While a number of molecular methods are available to identify critical pathways and potentially druggable targets, an agent ultimately must prove to be able to kill the tumor in question. Three principle strategies are most commonly employed to this end: culture of human tumor cell lines, xenografts of human tumor cell lines into immunocompromised mice, and genetic models of disease in model organisms. Each approach has benefi ts and detriments both practical and theoretical.
Culture of Tumor Cell Lines
Tumor cell lines that have been passaged multiple times in culture have accrued through such processing a definite but not entirely discernible variety of phenotypic and genetic changes. Their ultimate mimic of tumor cells in a native tumor environment is also challenged by the lack of the natural intratumor polyclonality of supporting cells, vasculature, paracrine signaling, and cell-to-cell signaling. Further, cultured cells lack the natural contribution to, or selective pressure from, ongoing immune surveillance, which likely has a heavy impact on tumors in a native host. Finally, the interactions of the drugs themselves with the host are diffi cult to model in culture systems. Some biological agents are cleaved or otherwise processed by the nontumor organ systems of hosts but will not be so processed in culture. The pharmacokinetics and distribution of other agents can invalidate the translation of in vitro data into the in vivo setting.
Xenografts of Human Tumor Cell Lines
Xenograft experiments for preclinical testing can address some of these pitfalls by better modeling some of the host processing of therapeutic agents and their delivery and distribution. These experiments even provide some of the host-tumor interactions missing from cell culture. Nonetheless, such host-tumor interactions, when based in immunocompromised mice with tumors implanted either subcutaneously or in the renal capsule, may have limited relation to the host-tumor interactions of a tumor arising in its natural primary or metastatic foci. In some ways, in terms of preclinical testing of drugs, xenografts become a more expensive version of cell-culture experiments. Xenograft experiments remain focused on cell lines but grow those cell lines in an environment that more closely resembles their growth in a tumor than a tissue fl ask can.
Genetic Models of Disease in Model Organisms
Genetic animal models of disease correct many of the challenges presented by cell culture and xenograft experiments, but they create other challenges. First, these animal tumors arise in another species, which limits some of the validity in translation to humans. Despite 98% coding sequence homology between the mouse and human genomes, there are obvious differences. 57 Second, while a much closer to natural host-tumor interaction is created in genetically modifi ed mice, it does not completely follow the natural history of the human tumor. Typically, genes will be activated or inactivated across an entire tissue type, meaning that some of the nontumor host cells will have genetic derangements that may or may not be important to their host function. Developmental effects of such alterations can arise that affect the lifespan and health of the host independent from tumorigenesis. Means to limit such effects are available, by temporal regulation of activation and density of activation in a tissue, but they cannot be removed completely. The greatest challenge to the use of genetic models of disease for preclinical testing is their expense. Generation of each model costs hundreds of thousands of dollars, well beyond the cost of media and culture plates.
Synovial Sarcoma Mouse Model
The Mario Capecchi Laboratory at the University of Utah, which participated in the discovery of many of the technologies used to generate genetically modifi ed mice, has recently developed two mouse models of syno- Fig 5. -Photomicrographs of sections stained with hematoxylin and eosin from a human synovial sarcoma (left), followed by a mouse synovial sarcoma (right). vial sarcoma. 10, 58 Both models offer different strengths for preclinical testing. Mice from both models develop sarcomas with complete penetrance. The sarcomas from these models mimic human synovial sarcoma both histologically and by expression profi le (comparing mouse to human homologs). These mice form no other tumors above background rates. The only genetic alteration in the mouse is the expression of human SYT-SSX2 in Myf5-expressing cells, without the need for additional genetic disruptions for potentiation. Sarcomas are fully developed in one of the models consistently by about 3 months of age, 10 minimizing expensive cage costs of a large colony awaiting sarcomagenesis.
These mouse models have been recently modifi ed further to include a luciferase reporter that is activated in the tumor cells but not the host background (Fig 3) . 59 This enables in vivo monitoring of tumor size and viability. The proposed experimental plan will be to expose groups of 3-month-old mice, with imaging-confi rmed tumors, to a variety of chemotherapeutic or biological agents. Noninvasive monitoring (Fig 4) , with luciferase imaging coordinated onto an overlaid plain radiograph anatomical reference, will measure the effects of each agent or combination of agents over time, followed by a histologic assessment (Fig 5) of tumors at necropsy.
Conclusions
Preclinical strategies for synovial sarcoma include cell-line culture and xenograft experiments, as well as genetically modifi ed model organisms. These approaches continue to improve our understanding and the number of potentially benefi cial treatment strategies available to patients. However, rather than driving each preclinically identifi ed therapeutic strategy forward into a prolonged, frustrating, and underpowered clinical trial, we hope to provide a means of prioritizing these strategies. The use of genetic models of disease is expensive and time-consuming, but far less so than the running of human clinical trials. These mouse trials can not only establish priorities for human clinical trials, but also provide valuable information regarding optimal dosing and drug delivery methods to guide human trial planning. The precious and limited resource of patients with synovial sarcoma requires forethought and planning to organize the maximal benefi t to them and to future patients. It is hoped that prospective assessment of the effects of a variety of agents and combinations of agents, including cytotoxic, antiangiogenic, proapoptotic, and antideacetylase compounds in the mouse model of synovial sarcoma, will help to prioritize these multiplied therapeutic strategies in order to guide the planning of future randomized controlled trials.
